Axatilimab added to CAR-T cell therapy for high-risk B-cell lymphoma
Tests axatilimab alongside CAR-T therapy in people with high-risk B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Axatilimab + CAR-T for High-Risk Lymphoma
Key facts
- Where
- Atlanta, United StatesSee the site
- Phase
- Phase 1
Where in United States
- Northside HospitalAtlanta, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northside Hospital, Inc.
- Trial code
- NCT07638982
- Record updated
- 16 October 2026
- Original description
Axatilimab + CAR-T in High-Risk LymphomaRead full original descriptionShow less
An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)
Axatilimab + CAR-T in High-Risk Lymphoma
Inclusion: Age ≥ 18 years; Histologically confirmed large B-cell lymphoma; Presence of one or more high-risk features; Eligible to receive CAR-T according to the FDA label; Measurable disease by CT or PET; Adequate organ function unless related to lymphoma involvement:; Pulse oximetry ≥ 92% on room air; Ejection Fraction ≥ 40%; ALT/AST < 5x ULN; Bilirubin < 3 x ULN; Calculated or measured creatinine Clearance ≥ 30 mL/min.
Exclusion: Allogeneic transplant within 100 days of enrollment; Second malignancy with a high metastatic potential within 3 years; Active CNS involvement. Treated CNS disease is allowed; Active HBV or HCV infection; Active uncontrolled infections; Known HIV positive status; Active acute or chronic graft versus host disease; History of acute or chronic pancreatitis; History of myositis; KPS <60.